Published in J Neurol on June 29, 2010
LATER models of neural decision behavior in choice tasks. Front Integr Neurosci (2014) 0.95
Eye movements in patients with neurodegenerative disorders. Nat Rev Neurol (2013) 0.91
Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci (2011) 0.84
An eye-tracking version of the trail-making test. PLoS One (2013) 0.83
Functional connectivity of primary motor cortex is dependent on genetic burden in prodromal Huntington disease. Brain Connect (2014) 0.81
Behavioral measures of saccade latency and inhibition in manifest and premanifest Huntington's disease. J Mot Behav (2011) 0.80
Movement sequencing in Huntington disease. World J Biol Psychiatry (2014) 0.80
Eye-tracking controlled cognitive function tests in patients with amyotrophic lateral sclerosis: a controlled proof-of-principle study. J Neurol (2015) 0.80
A retrospective analysis of hand tapping as a longitudinal marker of disease progression in Huntington's disease. BMC Neurol (2014) 0.79
Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease. J Neurol (2011) 0.77
Ocular motor abnormalities in neurodegenerative disorders. Eye (Lond) (2014) 0.76
Novel Nut and Bolt Task Quantifies Motor Deficits in Premanifest and Manifest Huntington's Disease. PLoS Curr (2015) 0.75
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet (2004) 4.73
Neural computation of log likelihood in control of saccadic eye movements. Nature (1995) 4.65
Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev (2000) 4.30
Saccades in presymptomatic and early stages of Huntington disease. Neurology (2006) 1.92
Using saccades as a research tool in the clinical neurosciences. Brain (2003) 1.89
Role for subthalamic nucleus neurons in switching from automatic to controlled eye movement. J Neurosci (2008) 1.88
Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord (2009) 1.73
Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology (2006) 1.52
Psychomotor, executive, and memory function in preclinical Huntington's disease. J Clin Exp Neuropsychol (2002) 1.51
Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. Arch Neurol (1999) 1.41
Profile of cognitive progression in early Huntington's disease. Neurology (2003) 1.35
Subtle changes among presymptomatic carriers of the Huntington's disease gene. J Neurol Neurosurg Psychiatry (2000) 1.32
Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci (2005) 1.31
Abnormal ocular motor control in Huntington's disease. Neurology (1983) 1.23
Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Res (2004) 1.20
Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene. Arch Neurol (2000) 1.19
A disorder of rapid eye movements in Huntington's chorea. Brain (1967) 1.16
Assessment of simple movements reflects impairment in Huntington's disease. Mov Disord (2006) 1.11
Saccades in Huntington's disease: initiation defects and distractibility. Neurology (1987) 1.10
Ocular motor abnormalities in Huntington's disease. Vision Res (1997) 1.04
The use of quantitative oculometry in the assessment of Huntington's disease. Exp Brain Res (2005) 1.01
Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. J Neurol (2008) 0.99
Oculomotor deficits indicate the progression of Huntington's disease. Prog Brain Res (2008) 0.98
Progression in prediagnostic Huntington disease. J Neurol Neurosurg Psychiatry (2009) 0.97
Bradykinesia in Huntington's disease. A prospective, follow-up study. J Neurol (2002) 0.94
Saccades in Huntington's disease: slowing and dysmetria. Neurology (1988) 0.90
Saccadic impairments in Huntington's disease. Exp Brain Res (2008) 0.89
Saccadometry: a new tool for evaluating presymptomatic Huntington patients. Neuroreport (2007) 0.88
Lifespan development of pro- and anti-saccades: multiple regression models for point estimates. Brain Res Dev Brain Res (2005) 0.86
Test-retest reliability of saccadic measures in subjects at risk for Huntington disease. Invest Ophthalmol Vis Sci (2009) 0.84
Visual attention in Huntington's disease: the effect of cueing on saccade latencies and manual reaction times. Neuropsychologia (1995) 0.80
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain (2009) 3.03
The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain (2003) 2.81
L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia (2003) 2.55
Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci (2005) 2.34
Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci (2003) 2.22
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry (2013) 2.20
A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity. J Exp Med (2011) 2.10
The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry (2011) 2.08
Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord (2013) 1.98
Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol (2007) 1.95
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Accuracy, information, and response time in a saccadic decision task. J Neurophysiol (2003) 1.82
Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain (2002) 1.75
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol (2013) 1.72
L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology (2006) 1.66
Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci (2004) 1.64
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2011) 1.62
Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol (2014) 1.55
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia (2004) 1.54
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Catechol O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci (2007) 1.50
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
A genome wide linkage disequilibrium screen in Parkinson's disease. J Neurol (2005) 1.41
The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders. Drugs Today (Barc) (2004) 1.40
Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain (2010) 1.35
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A (2009) 1.32
Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell (2010) 1.32
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res (2010) 1.28
Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype. Brain (2008) 1.28
The heterogeneity of idiopathic Parkinson's disease. J Neurol (2002) 1.28
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27
Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment. Eur J Neurosci (2006) 1.23
Habitual versus goal-directed action control in Parkinson disease. J Cogn Neurosci (2010) 1.22
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain (2006) 1.20
Health-related quality of life in Huntington's disease: Which factors matter most? Mov Disord (2009) 1.19
Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development (2013) 1.18
Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplant (2003) 1.17
GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro. Exp Neurol (2003) 1.17
A pathophysiological model of freezing of gait in Parkinson's disease. Parkinsonism Relat Disord (2008) 1.17
The current clinical management of Huntington's disease. Mov Disord (2008) 1.16
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain (2008) 1.15
Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett (2005) 1.15
Saccadic abnormalities in frontotemporal dementia. Neurology (2012) 1.15
Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia (2008) 1.15
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord (2009) 1.14
Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord (2012) 1.14
Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord (2004) 1.14
Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain (2003) 1.13
Huntington's disease patients have selective problems with insight. Mov Disord (2006) 1.12
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment. J Neurosci (2005) 1.12
The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. Exp Neurol (2008) 1.11
Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nat Clin Pract Neurol (2007) 1.11
Decreased hippocampal cell proliferation in R6/1 Huntington's mice. Neuroreport (2004) 1.10
Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci (2003) 1.10
The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol (2005) 1.09
The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry (2009) 1.09
Using executive heterogeneity to explore the nature of working memory deficits in Parkinson's disease. Neuropsychologia (2003) 1.06
Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets (2008) 1.05
Venous excess: a new approach to cardiovascular control and its teaching. J Appl Physiol (1985) (2004) 1.05
The time course of stimulus expectation in a saccadic decision task. J Neurophysiol (2007) 1.05
An internationally standardised antisaccade protocol. Vision Res (2013) 1.05
Health-related quality of life in Huntington's disease: a comparison of two generic instruments, SF-36 and SIP. Mov Disord (2004) 1.05
White matter pathology in Parkinson's disease: the effect of imaging protocol differences and relevance to executive function. Neuroimage (2012) 1.04
Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsychologia (2002) 1.02
Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs (2006) 1.01
The relation between anger and different forms of disgust: implications for emotion recognition impairments in Huntington's disease. Neuropsychologia (2010) 1.01
The use of quantitative oculometry in the assessment of Huntington's disease. Exp Brain Res (2005) 1.01
Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell (2012) 1.01
Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis (2012) 1.00
Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology (2013) 1.00
Neural cells from primary human striatal xenografts migrate extensively in the adult rat CNS. Eur J Neurosci (2002) 0.99
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease. J Neurol Neurosurg Psychiatry (2010) 0.98
Top-down attentional control in Parkinson's disease: salient considerations. J Cogn Neurosci (2010) 0.98
Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res (2006) 0.98
The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study. Brain (2012) 0.97
Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res (2007) 0.97
Cell therapy in Huntington disease. Neurosurg Focus (2008) 0.97
An anatomically constrained, stochastic model of eye movement control in reading. Psychol Rev (2005) 0.96
Antisaccades as decisions: LATER model predicts latency distributions and error responses. Eur J Neurosci (2012) 0.96
The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry (2013) 0.96
The spectrum of cognitive impairment in Lewy body diseases. Mov Disord (2014) 0.96
Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Mov Disord (2011) 0.95
Dopaminergic modulation of neurogenesis in the subventricular zone of the adult brain. Cell Cycle (2009) 0.95
Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr Neurol Neurosci Rep (2011) 0.94
Directional prediction by the saccadic system. Curr Biol (2008) 0.93
Predicting the timing of wrong decisions with LATER. Exp Brain Res (2011) 0.92
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias. Neurobiol Dis (2006) 0.92
Cell-based therapies for Parkinson's disease. Expert Rev Neurother (2011) 0.92
Task switching as a two-stage decision process. J Neurophysiol (2006) 0.92